Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimen

被引：43

作者：

Argov, Mirit ^{[1
]}

Kashi, Rina ^{[2
]}

Peer, Dan ^{[1
]}

Margalit, Rimona ^{[1
]}

机构：

[1] Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel

[2] Teva Pharmaceut Ind, Teva Innovat Ventures, Netanya, Israel

来源：

CANCER LETTERS | 2009年 / 274卷 / 01期

关键词：

Multidrug resistance; P-glycoprotein; Fluoxetine; Bevacizumab; Colon cancer; Doxorubicin;

D O I：

10.1016/j.canlet.2008.09.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pre-clinical Studies Of multidrug resistance (MDR) usually address severe resistance, yet moderate MDR is already clinically-impeding. The purpose of this study was to characterize moderate drug resistance in human colon cancer, and it's modulation by fluoxetine. In vitro fluoxetine enhanced doxorubicin's cytotoxicity (10-fold), increased doxorubicin's intracellular accumulation (32%) and decreased efflux of intracellular doxorubicin (70%). In vivo, mild treatment with a doxorubicin-fluoxetine combination slowed-down tumor progression significantly (p < 0.001 vs. doxorubicin alone). comparable to aggressive treatment with bevacizumab. Collectively, Our results suggest that combinations of fluoxetine with chemotherapeutic drugs (P-glycoprotein substrates) are worthy of further pursuit for moderate MDR in the clinic. (c) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：118 / 123

页数：6

共 43 条

[11]

Webb A., Cunningham D., Scarffe J.H., Harper P., Norman A., Joffe J.K., Hughes M., Mansi J., Findlay M., Hill A., Oates J., Nicolson M., Hickish T., O'Brien M., Iveson T., Watson M., Underhill C., Wardley A., Meehan M., Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer, J. Clin. Oncol., 15, pp. 261-267, (1997)

[12]

Wils J.A., Klein H.O., Wagener D.J., Bleiberg H., Reis H., Korsten F., Conroy T., Fickers M., Leyvraz S., Buyse M., Et al., Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group, J. Clin. Oncol., 9, pp. 827-831, (1991)

[13]

Robey R.W., Finley E.M., Oldham R.K., Barnett D.B., Ambudkar S.V., Et al., Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1<sup>®</sup>, Biochem. Pharmacol., 75, pp. 1302-1312, (2008)

[14]

Leonard G.D., Fojo T., Bates S.E., The role of ABC transporters in clinical practice, Oncologist, 8, pp. 411-424, (2003)

[15]

Litman T., Druley T.E., Stein W.D., Bates S.E., From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance, Cell. Mol. Life Sci., 58, pp. 931-959, (2001)

[16]

Lautier D., Canitrot Y., Deeley R.G., Cole S.P., Multidrug resistance mediated by the multidrug resistance protein (MRP) gene, Biochem. Pharmacol., 52, pp. 967-977, (1996)

[17]

Gottesman M.M., Fojo T., Bates S.E., Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, pp. 48-58, (2002)

[18]

Leslie E.M., Deeley R.G., Cole S.P., Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense, Toxicol. Appl. Pharmacol., 204, pp. 216-237, (2005)

[19]

Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M., Targeting multidrug resistance in cancer, Nat. Rev. Drug Discov., 5, pp. 219-234, (2006)

[20]

Collett A., Tanianis-Hughes J., Warhurst G., Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: a possible source of transporter mediated drug interactions?, Biochem. Pharmacol., 68, pp. 783-790, (2004)

← 1 2 3 4 5 →